ArticleBioengineering (Basel, Switzerland)2025
Microencapsulation of β-Glucosidase in Alginate Beads for Post-Rumen Release in Ruminant Gut.
Article in Bioengineering (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Nano/microencapsulation of feed additives for ruminal microbiome modulation and enteric methane mitigation in ruminants: a critical review.Frontiers in veterinary science · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
This study aimed to develop a microencapsulation formulation for efficient encapsulation of β-glucosidase to improve its stability in a rumen-like environment and sustain activity post-rumen in the ruminant gut. Various alginate-based formulations were evaluated to achieve high encapsulation efficiency (EE) and stability. These included control alginate beads (AB), microcapsules with chitosan (MCS), alginate-sucrose beads (AOS), alginate-sucrose-maltodextrin beads (AOMS), and alginate pectin beads (APB). The microcapsules were made using Buchi encapsulator B-390 with calcium chloride as the gelling solution. Alginate proved to be a suitable polymer for β-glucosidase encapsulation and <1 mm diameter microbeads were obtained across all formulations. Alginate alone (AB: 1% alginate, 0.2 U/mL β-glucosidase) showed low EE (3% ± 1.0) due to leakage and syneresis. Modifying the gelling solution with 0.1% chitosan (MCS) increased EE to 49 ± 2.64% by reducing alginate porosity. Further improvements were achieved by adding stabilizers to the alginate solution (AB), in addition to using the modified gelling solution (MCS): Adding sucrose (AOS) at 4% increased EE to 95.5 ± 2.08%, while adding sucrose (4%) and maltodextrin (2%) (AOMS) achieved 100 ± 2.16%. On the other hand, adding pectin (4%) (APB) to the alginate solution resulted in a lower EE of 40.5% ± 2.55, likely due to interference with alginate crosslinking. In vitro rumen fermentation showed a dry matter degradation of 42-54%, underscoring the need for more robust microcapsules. Encapsulation strategies, such as incorporation of additional protective layers, are essential to enhance bead stability, minimize degradation, and improve enzyme retention, to ensure efficient delivery and sustained enzymatic activity in the hindgut.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.